ALSO NOTED: Sanofi plans $100 million R&D facility; Vaccines safety group seeks public input; and much more...
Mumps outbreak spurs calls for a new vaccine
Health experts say that an outbreak of mumps two years ago among college students occurred even though most of them had received a recommended vaccine. And a number of physicians have concluded that
Crucell reports early-stage success with TB vaccine
Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is
Brazilian Dengue outbreak highlights vaccine need
An outbreak of dengue fever in and around Rio de Janeiro has afflicted more than 75,000 people since the beginning of the year, with 12 people dying in just the past week. No vaccine is available
SPOTLIGHT: Vaccine a success for human-to-human H5N1 case
A confirmed case of bird flu in China has confirmed that the threat of human-to-human contagion is still largely limited to the blood relatives of those infected. In an important case for vaccine
ALSO NOTED: GSK gains Rotarix approval; Bavarian Nordic touts smallpox data; and much more...
Vaccine Market GlaxoSmithKline has received FDA approval for Rotarix, a vaccine to stop the leading cause of diarrhea. The approval opens the way for a direct competitor to Merck's RotaReq. Rotarix
VaxDesign offers an alternative to animal studies
Time magazine profiles the work of VaxDesign, a five-year-old biotech company that has developed simulated human immune systems, mixing blood cells and faux tissue into a special construct that can
VaxGen faces possible liquidation after merger flops
The spectacularly unsuccessful VaxGen has called off an effort to
Ebola vaccines readied for first human trials
Researchers are pushing ahead with the first human trials of an ebola vaccine. Typical vaccines spark an antibody response against a threat. But with the lethal ebola, a successful vaccine has to
Cell Genesys pact highlights cancer vaccine value
Cell Genesys' $320 million partnership deal with Takeda for its
SPOTLIGHT: Novavax teams with GE on plants
Novavax plans to duplicate its Rockville, MD vaccine-making plant in a series of small plants scattered in developing nations, creating a ring of facilities that can produce vaccines to fight a bird
ALSO NOTED: Sinovac to produce H5N1 vaccine; CG Therapeutics develops new antibodies for tumor vaccine;and much more...
PharmAthene bids for big anthrax vaccine contract
PharmAthene is making a bid to develop a next-gen anthrax vaccine that can qualify for a $400 million government contract. The small Maryland developer is paying up to $40 million for a pair of
Individual investors buy into vaccination bond issue
Japanese investors have snapped up a $223 million bond program to fund vaccination campaigns in developing countries. The idea is that the investors' money will be used to pay for the upfront costs
Iomai gets boost in bird flu vaccine adjuvant study
In a Phase I/II trial, three out of every four people in a study of 500 people using an adjuvant patch developed by Iomai achieved a protective immune response after a single dose. That compares to
SPOTLIGHT: Autism link researcher faces charges
Dr. Andrew Wakefield and two colleagues will begin their defense today against charges they violated ethics guidelines in the U.K. while developing a 1998 paper that linked autism to vaccines. That
ALSO NOTED: Program eliminates polio in Somalia; New insight into malaria vaccine; and much more...
Vaccine Market A group of 10,000 volunteers and health workers has eliminated polio in Somalia through an ambitious vaccination program. And workers say the experience could help officials eradicate
Vietnamese launch human trial of bird flu vaccine
A Vietnamese company is beginning a human trial of a new bird flu vaccine. Vabiotech, a subsidiary of Vietnam's National Institute of Hygiene and Epidemiology, plans eight months of testing in a

